Catalyst
Slingshot members are tracking this event:
Roche's (RHHBY) Lucentis sBLA Granted Priority Review by FDA for Treatment of Myopic Choroidal Neovascularization
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| RHHBY |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 11, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Lucentis, Sbla, Myopic Choroidal Neovascularization, Fda
